GT Biopharma Stock Quote GTBP - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

2.05

Bid

1.71

Ask

2.17

Volume

0.00 Day's Range 0.00

1.95 52 Week Range 10.6599

Market Cap

4.58M

Previous Close

2.05

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

12,636

Shares Outstanding

2,234,328

Dividend Yield

PE Ratio

-0.60

Earnings Per Share (EPS)

-3.4

Revenue

Net Profit

-7.6M

GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cance... GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.gtbiopharma.com

Headquarters

Wilmington, Delaware, USA

Founded

GT Biopharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GTBP. The last closing price for GT Biopharma was $2.05. Over the last year, GT Biopharma shares have traded in a share price range of $ 1.95 to $ 10.6599.

GT Biopharma currently has 2,234,328 shares outstanding. The market capitalization of GT Biopharma is $4.58 million. GT Biopharma has a price to earnings ratio (PE ratio) of -0.60.

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.12	-5.52995391705	2.17	2.29	2.05	13860	2.11778568	CS
4	-0.19	-8.48214285714	2.24	2.29	1.95	8760	2.12286465	CS
12	-0.75	-26.7857142857	2.8	2.96	1.95	12636	2.48612013	CS
26	-2.6	-55.9139784946	4.65	10.6599	1.95	706977	7.13209397	CS
52	-5.42	-72.5568942436	7.47	10.6599	1.95	403078	7.1161016	CS
156	-216.35	-99.0613553114	218.4	224.7	1.95	275914	33.6953572	CS
260	-162.95	-98.7575757576	165	591.993	1.95	313814	108.62967272	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NUKKNukkleus Inc	$ 0.3715 (74.82%)	3.33M
TGLTreasure Global Inc	$ 0.9294 (36.62%)	460.26k
ULYUrgent ly Inc	$ 1.12 (26.97%)	333.41k
GSIWGarden Stage Ltd	$ 1.625 (21.27%)	824.92k
BDRXBiodexa Pharmaceuticals PLC	$ 0.35 (19.82%)	3.51k
PRFXPainReform Ltd	$ 0.60 (-22.19%)	1.95k
ZJYLJin Medical International Ltd	$ 3.24 (-20.59%)	1.7k
FRESFresh2 Group Ltd	$ 1.39 (-19.65%)	88
ADTXAditxt Inc	$ 0.3111 (-18.69%)	26.55k
MYNZMainz BioMed NV	$ 0.2006 (-17.45%)	144.2k
NUKKNukkleus Inc	$ 0.3715 (74.82%)	3.33M
GSIWGarden Stage Ltd	$ 1.625 (21.27%)	824.92k
TGLTreasure Global Inc	$ 0.9294 (36.62%)	460.26k
ULYUrgent ly Inc	$ 1.12 (26.97%)	333.41k
INTCIntel Corporation	$ 22.70 (3.94%)	322.42k